Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. J of Skin 2019, 3 (2), 169. https://doi.org/10.25251/skin.3.2.9.